Table 1. Patient characteristics and association with probable depression on BCD.
|
Probable depression on BCD |
||||
|---|---|---|---|---|
| No | Yes | Total | P-value | |
| Sex | ||||
| Male | 34 (63%) | 20 (37%) | 54 | 0.53a |
| Female | 32 (70%) | 14 (30%) | 46 | |
| Age group | ||||
| ⩽30 | 3 (43%) | 4 (57%) | 7 | |
| 30–39 | 5 (50%) | 5 (50%) | 10 | |
| 40–49 | 9 (69%) | 4 (31%) | 13 | |
| 50–59 | 16 (62%) | 10 (38%) | 26 | 0.11b |
| 60–69 | 22 (76%) | 7 (24%) | 29 | |
| 70–79 | 9 (75%) | 3 (25%) | 12 | |
| ⩾80 | 1 (50%) | 1 (50%) | 2 | |
| Living arrangements | ||||
| With others | 56 (64%) | 31 (36%) | 87 | 0.53a |
| Alone | 10 (77%) | 3 (23%) | 13 | |
| ECOG performance status | ||||
| 0 | 15 (94%) | 1 (6%) | 16 | |
| 1 | 26 (67%) | 13 (33%) | 39 | |
| 2 | 16 (57%) | 12 (43%) | 28 | 0.0064c |
| 3 | 9 (56%) | 7 (44%) | 16 | |
| 4 | 0 (0%) | 1 (100%) | 1 | |
| Type of cancer | ||||
| Gastrointestinal | 18 (78%) | 5 (22%) | 23 | |
| Breast | 14 (67%) | 7 (33%) | 21 | |
| Head and neck | 7 (70%) | 3 (30%) | 10 | |
| Sarcoma | 6 (60%) | 4 (40%) | 10 | |
| Skin | 5 (71%) | 2 (29%) | 7 | 0.31d |
| Gynaecological | 3 (50%) | 3 (50%) | 6 | |
| Lung | 2 (33%) | 4 (67%) | 6 | |
| Haematological | 4 (100%) | 0 (0%) | 4 | |
| Othere | 7 (54%) | 6 (46%) | 13 | |
| Disease status | ||||
| No evidence of disease | 12 (75%) | 4 (25%) | 16 | 0.88d |
| Localised disease, asymptomatic | 2 (50%) | 2 (50%) | 4 | |
| Localised disease, symptomatic | 13 (65%) | 7 (35%) | 20 | |
| Metastatic disease, asymptomatic | 7 (70%) | 3 (30%) | 10 | |
| Metastatic disease, symptomatic | 32 (64%) | 18 (36%) | 50 | |
| No evidence of disease | 12 (75%) | 4 (25%) | 16 | |
| Localised disease | 15 (63%) | 9 (38%) | 24 | 0.34c |
| Metastatic disease | 39 (65%) | 21 (35%) | 60 | |
| Symptoms | ||||
| Absent | 21 (70%) | 9 (30%) | 30 | 0.38f |
| Present | 45 (64%) | 25 (36%) | 70 | |
| Pain | ||||
| No pain | 27 (77%) | 8 (23%) | 35 | |
| Mild pain | 14 (70%) | 6 (30%) | 20 | |
| Discomforting pain | 15 (60%) | 10 (40%) | 25 | 0.045c |
| Distressing pain | 6 (40%) | 9 (60%) | 15 | |
| Horrible pain | 3 (75%) | 1 (25%) | 4 | |
| Excruciating pain | 1 (100%) | 0 (0%) | 1 | |
| Goals of therapy | ||||
| Curative/adjuvant | 26 (67%) | 13 (33%) | 39 | 1.00a |
| Palliative | 40 (66%) | 21 (34%) | 61 | |
a
Fisher's exact test (two-sided).
b
Wilcoxon–Mann–Whitney test using actual ages (two-sided).
c
Cochran–Armitage test for trend (one-sided).
d
Pearson χ2 test (two-sided).
e
Other cancers were as follows: testicular seminoma, three; metastatic carcinoma of unknown primary, two; soft tissue neuroendocrine tumour, one; renal cell carcinoma, one; prostate, one; phaeochromocytoma, one; peripheral neuroectodermal tumour, one; medullary thyroid carcinoma, one; fibrous histiocytoma, one; carcinoid tumour, one.
f
Fisher's exact test (one-sided).